Azlocillin can be the potential drug candidate against drug-tolerant *Borrelia burgdorferi sensu stricto* JLB31

Venkata Raveendra Pothineni1, Hari-Hara S. K. Potula1, Aditya Ambati2, Venkata Vamsee Aditya Mallajosyula3, Brindha Sridharan6, Mohammed Inayathullah1, Mohamed Sohail Ahmed1 & Jayakumar Rajadas1,4,5*

Lyme disease is one of the most common vector-borne diseases, reporting more than 300,000 cases annually in the United States. Treating Lyme disease during its initial stages with traditional tetracycline antibiotics is effective. However, 10–20% of patients treated with antibiotic therapy still show prolonged symptoms of fatigue, musculoskeletal pain, and perceived cognitive impairment. When these symptoms persist for more than 6 months to years after completing conventional antibiotics treatment are called post-treatment Lyme disease syndrome (PTLDS). Though the exact reason for the prolongation of post treatment symptoms is not known, the growing evidence from recent studies suggests it might be due to the existence of drug-tolerant persisters. In order to identify effective drug molecules that kill drug-tolerant *borrelia* we have tested two antibiotics, azlocillin and cefotaxime that were identified by us earlier. The *in vitro* efficacy studies of azlocillin and cefotaxime on drug-tolerant persisters were done by semisolid plating method. The results obtained were compared with one of the currently prescribed antibiotic doxycycline. We found that azlocillin completely kills late log phase and 7–10 days old stationary phase *B. burgdorferi*. Our results also demonstrate that azlocillin and cefotaxime can effectively kill *in vitro* doxycycline-tolerant *B. burgdorferi*. Moreover, the combination drug treatment of azlocillin and cefotaxime effectively killed doxycycline-tolerant *B. burgdorferi*. Furthermore, when tested *in vivo*, azlocillin has shown good efficacy against *B. burgdorferi* in mice model. These seminal findings strongly suggest that azlocillin can be effective in treating *B. burgdorferi sensu stricto* JLB31 infection and furthermore in depth research is necessary to evaluate its potential use for Lyme disease therapy.

Lyme disease is a major vector-borne disease in the United States caused by *Borrelia burgdorferi sensu lato* which affects more than 300,000 people annually1–3. Lyme disease affects various organs such as brain, skin, heart, joints, and nervous systems4–6. The symptoms of Lyme disease are erythema migrans, fatigue, fever, headache, chills, muscle and joint pain7,8. Current antibiotic treatment for Lyme disease is effective during early stages of disease and cures the infection in most patients9. However, 10–20% of patients undergone antibiotic treatment still experience symptoms like pain, fatigue, arthralgia, and cognitive problems. If these symptoms prolong more than 6 months after treatment, it is referred to as Post-treatment Lyme Disease Syndrome (PTLDS)10–12. Though the exact root cause for PTLDS is not known, research evidences suggests it might be presence of persister forms of *B. burgdorferi* or due to impaired immunological response13,14. Many research studies has shown that *B.

---

1Biomaterials and Advanced Drug Delivery, Stanford Cardiovascular Pharmacology Division, Cardiovascular Institute, Stanford University School of Medicine, Palo Alto, California, 94304, USA. 2Center for Sleep sciences and medicine, Department of Psychiatry and Behavioral Sciences, School of Medicine, Stanford University, Palo Alto, California, 94304, USA. 3Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, 94305, USA. 4Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University School of Medicine, Palo Alto, California, 94304, USA. 5Bioengineering and Therapeutic Sciences, UCSF School of Pharmacy, University of California, San Francisco, CA, 94158, USA. 6Department of Plant Biology and Biotechnology, Loyola College, Chennai, 600 034, Tamil Nadu, India. *email: jayraja@stanford.edu
B. burgdorferi establishes persistent infections after antibiotic treatment in various animal models. A recent study in humans demonstrated that B. burgdorferi DNA was identified in PTDLS patient by xenodiagnosis but unable to culture viable spirochete. In about 85% of Lyme arthritis patients, B. burgdorferi DNA was detected in synovial fluid by polymerase chain reaction (PCR) testing. Although the exact mechanism of how the Borrelia persists in an immunocompetent host is not known, a number of theories have been proposed based on scientific evidences. The probable mechanisms as evidenced by scientific literature are the persister formation, evading immune system by hiding in the privileged sites, surface lipoproteins modifications to avoid antigenic responses, biofilm formation and immunomodulation. Sapi et al showed the presence of Borrelia biofilm in the Borrelia infected Lymphocytes.

Like in other pathogens, several in vitro studies showed the evidence that B. burgdorferi also forms drug-tolerant persisters when treated with antibiotics. These studies reveals that a small subpopulation of dormant B. burgdorferi persisters still survives with current Lyme therapy antibiotics. Recently, it was also shown that B. burgdorferi infection caused by persistent biofilm/microcolonies could not be eradicated by currently prescribed drugs like doxycycline and ceftriaxone. Due to increasing number of chronic lyme disease cases, there is a urgent need to find effective drug molecules which can target Borrelia persisters and Lyme associated disorders.

Taking in to consideration of the limiting effects of standard antibiotics and our search to identify safe and effective molecules to kill the persisters of B. burgdorferi, we screened 7450 chemical compounds (80% FDA approved) from several different libraries, using a BacTiter-Glo Assay. We have identified nearly 300 hit molecules and evaluated the top 50 hit molecules by the entire study. Our results showed that the both tested antibiotics, cefotaxime at high concentration could able to completely (100%) kill log phase culture of B. burgdorferi respectively (Fig. 1A). Similarly, azlocillin at 20µg/ml concentration also eliminated stationary phase B. burgdorferi persisters completely. However, cefotaxime at highest concentration of 80µg/ml could able to kill (80%) of the stationary phase B. burgdorferi persisters (Fig. 1B). More importantly, cefotaxime at increased concentrations from 20 to 80µg/ml did not vary much in killing of a small persister fraction of surviving cells. The doxycycline, a bacteriostatic couldn’t able to kill both the log phase and stationary phase B. burgdorferi cultures at higher concentrations of 80µg/ml. More than 1000 stationary phase cells were survived at doxycycline concentration of 80µg/ml. The mitomycin C at 1.25µg/ml concentration killed B. burgdorferi both in log and stationary phase persisters as reported earlier.

Results

Eradiation of B. burgdorferi persisters by Azlocillin and Cefotaxime. In the present study, we first assessed the potency of azlocillin and cefotaxime against B. burgdorferi in dose dependent manner in both log and also stationary phase cultures of B. burgdorferi along with standard Lyme antibiotic (doxycycline). We used mitomycin C as a positive control and determined viability by colony forming unit (CFU) counts throughout the entire study. Our results showed that the both tested antibiotics, cefotaxime at high concentration 40µg/ml and azlocillin at very low concentration 2.5µg/ml could able to completely (100%) kill log phase culture of B. burgdorferi respectively (Fig. 1A). Similarly, azlocillin at 20µg/ml concentration also eliminated stationary phase B. burgdorferi persisters completely. However, cefotaxime at highest concentration of 80µg/ml could able to kill (80%) of the stationary phase B. burgdorferi persisters (Fig. 1B). More importantly, cefotaxime at increased concentrations from 20 to 80µg/ml did not vary much in killing of a small persister fraction of surviving cells. The doxycycline, a bacteriostatic couldn’t able to kill both the log phase and stationary phase B. burgdorferi cultures at higher concentrations of 80µg/ml. More than 1000 stationary phase cells were survived at doxycycline concentration of 80µg/ml. The mitomycin C at 1.25µg/ml concentration killed B. burgdorferi both in log and stationary phase persisters as reported earlier.

B. burgdorferi persisters induced by doxycycline are more tolerant to drugs. Doxycycline is most commonly used drug to treat Lyme disease among the antibiotics prescribed for Lyme disease. Many researchers have shown that doxycycline doesn’t kill B. burgdorferi completely and some population of drug-tolerant B. burgdorferi still exists. The human maximum drug concentration (Cmax) range of doxycycline is between 2.6–5.9µg/ml and has a half-life of 14 to 24 h. At this doxycycline Cmax concentration range, 1000–10000 cells/ml of log phase Borrelia and 10000–200000 cells/ml of stationary phase Borrelia still exists from the initial inoculum of 10^8 cells/ml. The fraction of B. burgdorferi persisters survived against doxycycline is significantly high. Further, to find drugs that can effectively kill doxycycline-tolerant B. burgdorferi, we have tested both azlocillin and cefotaxime on doxycycline-tolerant B. burgdorferi persisters. The doxycycline-tolerant B. burgdorferi that survived at both log phase and stationary phase were treated with 20 and 40µg/ml of azlocillin and also resuspended again with doxycycline for 7 days and plated on BSK-II agarose medium for CFU. In log phase cultures, the doxycycline-tolerant B. burgdorferi that survived at 2.5 and 5µg/ml of doxycycline were reduced to < 50 cells/ml by azlocillin. Azlocillin completely eliminated all the doxycycline-tolerant B. burgdorferi survived at 10µg/ml of doxycycline treatment. As expected and also shown by other groups, B. burgdorferi in stationary phase were more tolerant to doxycycline. Azlocillin significantly reduced stationary phase drug-tolerant persisters survived at 2.5 and 5µg/ml of doxycycline treatment to < 300 cells. Stationary phase B. burgdorferi that persisted at 10µg/ml of doxycycline were effectively killed to < 200 by azlocillin. Azlocillin has effectively eliminated 99% of doxycycline-tolerant B. burgdorferi persisters both in log and stationary phase cultures.

The drug-tolerant B. burgdorferi persisters which persisted after treating with doxycycline were also tested with 40 and 80µg/ml cefotaxime. Cefotaxime effectively kills the log phase doxycycline-tolerant B. burgdorferi to <10 cells (Fig. 3A). Furthermore, cefotaxime also killed stationary phase B. burgdorferi to <2500 cells, which are survived at 2.5 and 5µg/ml doxycycline. Doxycycline-tolerant B. burgdorferi that persisted at 10µg/ml doxycycline were killed effectively to <200 cells when treated with cefotaxime. When the doxycycline-tolerant B. burgdorferi that persisted were resuspended again with doxycycline, no drastic reduction of B. burgdorferi was observed. It is statistically significant for B. burgdorferi treated at 2.5µg/ml, the decrease in no of B.
burgdorferi cell growth is less with both azlocillin and cefotaxime treatment. At 5 and 10 μg/ml of doxycycline resuspension treatment no major reduction of Burgdorferi growth was observed. At both log and stationary phase, significant growth reduction was also observed with azlocillin and cefotaxime treatment when compared to doxycycline resuspension (Figs. 2 and 3).

We also tested whether the colonies survived after doxycycline-tolerant Burgdorferi persisters treated with azlocillin repeatedly had acquired any resistance towards drugs. So, we picked and regrown doxycycline-tolerant Burgdorferi persisters that were treated with 10 μg/ml of azlocillin for 7 days in BSK-II medium. Then the regrown Burgdorferi were tested by treating them again with 10, 20 μg/ml of azlocillin. These results observed were same as earlier and only less than 10 cells were survived (Fig. 4). From these results we have found that drug-tolerant Burgdorferi persisters that survived, were treated with azlocillin did not acquire any antibiotic resistance mechanism. Our observation showed Burgdorferi persisted might be typical stochastic persister cells which was shown earlier by other researchers 19, 25, 32.

Azlocillin and Cefotaxime combination increases efficacy. It is known that some antibiotics act synergistically or more effective when used in combinations 33. In our further studies we have tested combinations of azlocillin and cefotaxime to identify whether they can increase the efficiency of killing drug-tolerant persister cells. The azlocillin and cefotaxime combinations could able to kill drug-tolerant Burgdorferi persisters formed at 5 and 10 μg/ml of log phase cultures. The azlocillin (20 μg and 40 μg) and cefotaxime (80 μg) combinations reduced 2.5 μg/ml of doxycycline treated persisters (log phase) to less than 10 cells/ml (Fig. 5A). Furthermore, combination of 40 μg/ml azlocillin and 80 μg/ml cefotaxime effectively could able to kill stationary phase doxycycline (2.5, 5 and 10 μg/ml) treated persister cultures. The drug-tolerant persisters survived in this combination were <10 cells/ml (Fig. 5B). Other drug combinations of azlocillin and cefotaxime (40 μg/ml azlocillin and 40 μg/ml cefotaxime; 20 μg/ml azlocillin and 80 μg/ml cefotaxime) shown in Fig. 5B reduced the persisters generated by doxycycline (at concentrations 2.5, 5 and 10 μg/ml) to 10 to 100 cells/ml. Overall, the drug combinations of 40 μg/ml azlocillin and 80 μg/ml cefotaxime is much more effective in killing persisters than using azlocillin alone. The azlocillin and cefotaxime combination significantly kills doxycycline-tolerant Burgdorferi than doxycycline resuspension at both log and stationary phases.
Time kill studies of *B. burgdorferi* by Azlocillin. We have observed that azlocillin kills 100% of normal *B. burgdorferi* cells and more than 99% of drug-tolerant *B. burgdorferi* persisters at 20 and 40 μg/ml azlocillin concentrations. To determine the rate of antimicrobial activity of azlocillin sodium with time, 10^6/ml *B. burgdorferi* (JLB31 strain) was exposed to concentrations of 20 and 40 μg/ml azlocillin drug. In 2 hrs the initial *B. burgdorferi* inoculum decreased more than 1-log10-unit at both the concentrations of azlocillin sodium (Fig. 6). By 24hrs *B. burgdorferi* load is decreased to 10,000 cells/ml and by 48 hrs bacteria were reduced to 100 cells/ml (99.9%). By 96 hrs, azlocillin has killed all *B. burgdorferi* persisters at both concentrations in stationary phase cultures. The doxycycline Cmax concentration range of 5 μg/ml and 10 μg/ml (2x of Cmax) was used for effectivity comparison. In control, the *B. burgdorferi* growth increased to 10^8 cells/ml.

**In silico analysis of azlocillin binding to PBPs and Clp proteases.** Since the 3D structure for the pencillin-binding protein of *Borrelia burgdorferi* (PBP-3Bb) has not been resolved, its 3D structure was predicted using homology modeling. Penicillin-binding protein 1A (PBP-1A) of *Pseudomonas aeruginosa* (PDB ID: 5DF7), for which 3D structure is available (PDB ID: 4OON), was found to have 39% sequence similarity with PBP-3Bb. Therefore, 4OON was used as the template to build the 3D structure of PBP-3Bb; in the modeled structure of PBP-3Bb, 87.1% of the amino acids were observed to be in the most favored region while 11.4% were in addition allowed region of the Ramachandran plot (supplementary Figure 1). In addition, the modeled structure showed RMSD value 0.235 Å with that of the template structure despite the moderate sequence similarity observed between these two proteins. These results indicate the reliability of the modeled structure for further
usage. Therefore, azlocillin was docked with this predicted structure of PBP-3Bb and found azlocillin binding with it strongly (−8.5 kcal/mol) (Fig. 7a). Five amino acids namely, GLN459, LYS507, ASN523, GLY567, GLN671 were observed to make hydrogen bond interaction with that of azlocillin. Further, six more amino acids, namely TRP673, THR669, SER462, GLY461, THR670 and SER521 were found to interact with azlocillin by van der Waals interaction (Fig. 7b). When azlocillin was docked with the PBP of \( P. \) aeruginosa (4OON) which was used as the template to model PBP-3Bb, it was observed to bind in the same binding cavity as that of PBP-3Bb with similar binding affinity (−8.7 kcal/mol), since these two proteins folded similarly.

As clpP was reported to be upregulated by doxycycline-tolerant \( B. \) burgdorferi, we speculated that azlocillin mode of action against \( B. \) burgdorferi through inhibition of any of the Clp protease subunits, because we found azlocillin is active against doxycycline-induced persistors of \( B. \) burgdorferi\(^32\). Based on these reports, we have performed molecular modeling and molecular docking on five different protease proteolytic subunits, ClpP, ClpP1, ClpP2, ClpA and ClpX of \( B. \) burgdorferi. Azlocillin was found to bind with these five protease subunits with similar binding affinity as that of with PBP-3Bb (ClpP: −9.9, ClpP2: −9, ClpP1: −8.9, ClpA: −8.8 (kcal/mol). As the 3D structure for clpX of \( B. \) burgdorferi has not been resolved, its 3D structure was predicted using homology modeling based on clpX of \( E. \) coli (PDB ID 3HTE) (supplementary Figure 2). Five amino acids from clpX namely, LYS123, GLY122, THR124, LYS128 and ARG301 were found to interact with azlocillin by hydrogen bonding while four more amino acids namely, GLY120, ARG364, GLU109, GLN330 made with van der Waals interactions with azlocillin (Fig. 7c,d).
B. burgdorferi cline groups. In addition to it, B. burgdorferi treated mice. In the cefotaxime treated mice, 1 of the 4 mice showed positive for ear cultures.

The B. burgdorferi spreads to different organs of body like heart, spleen, kidney and joints etc. For all the mice treated with drugs B. burgdorferi to 14 and 21 days. The infection reaches high titre between 14 and 21 days of postinfection and B. burgdorferi identify a highly effective molecule that can clear infection we have extended infection time periods and for qPCR analysis of ear and urinary bladder. As expected, all the mice of the naïve group shown negative for ear cultures group (Table 1). In saline treated (control) group, all the mice showed positive for ear cultures and also for qPCR DNA was detected by qPCR in 2 of 4 mice from ear and also in urinary bladder of all the 4 mice of cefotaxime concentration of B. burgdorferi (50 mg/kg), doxycycline (50 mg/kg) and cefotaxime (30 mg/kg) once a day for five days post 7, 14 and 21 days of B. burgdorferi infected C3H mice with infective dose of rision to one of the currently prescribed drug doxycycline. In order to identify more effective drugs, we have efficacy of compounds azlocillin and cefotaxime were tested in 5–6 week old female C3H/HeN mice in compa-

B. burgdorferi have killed B. burgdorferi effectively at low MIC and MBC concentration. Based on these results, the efficacy of compounds azlocillin and cefotaxime were tested in 5–6 week old female C3H/HeN mice in compari-

growth was observed from the ears cultured in all the mice treated with azlocillin and doxycycline groups. In addition to it, B. burgdorferi specific DNA by qPCR was not observed in azlocillin and doxycycline treated mice. In the cefotaxime treated mice, 1 of the 4 mice showed positive for ear cultures. The B. burgdorferi DNA was detected by qPCR in 2 of 4 mice from ear and also in urinary bladder of all the 4 mice of cetofaxime group (Table 1). In saline treated (control) group, all the mice showed positive for ear cultures and also for qPCR analysis of ear and urinary bladder. As expected, all the mice of the naïve group shown negative for ear cultures and for qPCR analysis of ear and urinary bladder.

Both azlocillin and doxycycline treatment has shown similar efficacy in the mice infected for 7 days. To identify a highly effective molecule that can clear B. burgdorferi infection we have extended infection time periods to 14 and 21 days. The B. burgdorferi infection reaches high titre between 14 and 21 days of postinfec
tion and spreads to different organs of body like heart, spleen, kidney and joints etc. For all the mice treated with drugs after 14 and 21 days of B. burgdorferi infection, ear and urinary bladders were collected for whole-DNA extraction and quantitative PCR (qPCR) analysis. In all the 4 mice infected for 14 days and treated with cefotaxime, high amount of B. burgdorferi DNA was detected in both ear and urinary bladder. After 14 days of infection and doxycycline treatment, the B. burgdorferi DNA was detected in 3 of 7 mice in ear tissue and 1 of 7 mice in urinary bladder. In one of the doxycycline treated mice B. burgdorferi DNA was present in both ear (high amount) and urinary bladder. However, for azlocillin treatment, only 2 of 8 mice has shown B. burgdorferi DNA in ear. No B. burgdorferi DNA was present in urinary bladder of all the 8 mice treated with azlocillin (Table 2). In all the mice treated with azlocillin after 21 days of infection, no B. burgdorferi DNA was detected in both ear and urinary bladder. But in the doxycycline group, 1 of 3 mice was detected positive for B. burgdorferi DNA in ear tissue and no DNA was found in urinary bladders (Table 3). As expected all the mice (14 and 21 days of infection) in control group (untreated) showed large amount of B. burgdorferi DNA both in ear and urinary bladder. No presence of bacterial DNA in naïve mice. No B. burgdorferi was observed in ear cultures of azlocillin and doxycycline treated mice at day 14 and day 21. In the cefotaxime treated mice, 3 of the 4 mice showed positive for ear cultures of 14 day infection. All the mice infected for 14 and 21 days in saline (control) group has B. burgdorferi growth in cultures. No B. burgdorferi growth was observed in uninfected naïve group at day 14 and day 21.
**Discussion**

Like many bacteria *B. burgdorferi* also forms persisters due to external stimuli like depriving of nutrients, pH and antibiotics etc. The mechanism by which *B. burgdorferi* form persisters is unknown so far. Many bacteria uses different types of mechanisms for the formation of persisters. The *E. coli* and *S. Typhimurium* bacteria use identified redundant toxin-antitoxin (TA) modules for persister formation. Toxins help in persister formation by decreasing the energy level of cells or by inhibiting protein synthesis. The persisters generated by antibiotics are biphasic, with a small subpopulation of surviving cells which are not genetically modified.

To identify drugs that can completely eliminate *B. burgdorferi* persisters, we have tested drugs azlocillin and cefotaxime on log and stationary phase cultures. The main criteria for selection of these drugs are based on their safety and good efficacy with low MIC and MBC values. The cefotaxime has killed log phase culture at 40 μg/ml and unable to kill all the stationary phase cultures even at 80 μg/ml. The azlocillin has eradicated *B. burgdorferi* log phase culture at 2.5 μg/ml and stationary phase culture at 20 μg/ml. So far, azlocillin is the FDA approved drug shown that killed both *B. burgdorferi* log phase and stationary phase cultures completely. Azlocillin is an acylated form of ampicillin which is similar to the antibiotics mezlocillin and piperacillin. It is a broad range β-lactam antibiotic kills many pathogens which also show high activity against *Pseudomonas aeruginosa*. It is well known...
that cell wall-acting drugs do not kill nongrowing bacteria. One of the reason azlocillin killing *B. burgdorferi* persists is that the stationary phase culture represents a steady state of growing and dying cells. It is shown recently that the stationary phase *B. burgdorferi* synthesize peptidoglycan at the poles and also in the middle of the cell\(^1\). Due to the production of peptidoglycan in stationary phase *B. burgdorferi*, other cell wall acting drugs like ceftriaxone and vancomycin were killing stationary phase *B. burgdorferi* very efficiently\(^3\). As azlocillin targets cell wall synthesis, this might be one of the reason that it is killing drug-tolerant persisters. It is also shown that β-lactams killing nonreplicative *M. tuberculosis* bacteria effectively when used in combination with meropenem\(^4\).

The serum levels of azlocillin and cefotaxime in the blood are higher than the MBC values to kill the *B. burgdorferi*. The Cmax concentration of cefotaxime is 125 μg/ml and azlocillin is 236.55 +/− 12.9 μg/ml, which is 10 times more than the MBC value\(^4\). The Cmax concentration of doxycycline is in the range of 2.6–5.9 μg/ml and

---

**Figure 6.** Time-dependent killing of *B. burgdorferi* by Azlocillin. The stationary phase *B. burgdorferi* were treated with azlocillin with concentrations of 20, and 40 μg/ml and doxycycline 5 and 10 μg/ml. At all indicated time points an aliquot was taken, washed, diluted, and plated on semisolid BSK-II medium for CFU counts (n = 3). The control has no drugs. Error bars represent standard errors.

**Figure 7.** Molecular interactions of azlocillin with PBP-Bb (a and b) and with clpX of *B. burgdorferi* (c and d). Figures a and c displays the protein in ribbon (gray in color) and azlocillin in stick form (red in color); figures b and d shows the 2D view of molecular interactions in which azlocillin is shown in line form (red in color) and hydrogen bonds in dashed lines and respective amino acids in spheres (green in color); those amino acids which make van der Waals interactions are displayed spheres (light green in color).
has a half-life of 14 to 24 h\textsuperscript{30}. It is shown that at this Cmax concentration of doxycycline all the \textit{B. burgdorferi} cannot be cleared, still some subpopulation persists and exists\textsuperscript{13,19,25,28,29}. Researchers has shown when the stationary phase \textit{B. burgdorferi} were treated with Cmax concentration (2.6–5.9 μg/ml) of doxycycline nearly 10⁴–10⁶ cells still survived\textsuperscript{19,29}. At this Cmax concentration of doxycycline, we also found 10³–10⁴ of log phase \textit{Borrelia} and 10⁴–10⁵ cells/ml of stationary phase \textit{Borrelia} still exists. The fraction of \textit{B. burgdorferi} subpopulation survived with doxycycline treatment is significantly high. The resuspension of doxycycline-tolerant persisters again with doxycycline did not show much effect as like previous studies\textsuperscript{29}. This is because the Cmax concentrations of doxycycline used to kill \textit{B. burgdorferi} is not sufficient\textsuperscript{11,19}. In our study, we have shown for the first time that azlocillin, an FDA approved drug is killing nearly 99.9% of doxycycline-tolerant \textit{B. burgdorferi} persisters that formed at Cmax concentrations, both in log phase and stationary phase cultures. In comparision to azlocillin, cefotaxime did not eliminate doxycycline-tolerant \textit{B. burgdorferi} persisters as efficiently and nearly 10³ cells/ml of \textit{B. burgdorferi} persisters were survived when treated with 40 μg/ml and 80 μg/ml of cefotaxime. So, the results showed azlocillin effectively kills the drug-tolerant \textit{B. burgdorferi} persisters. Though both antibiotics are β-lactams, azlocillin might use different mechanism in killing persisters. When used drug combination of azlocillin and cefotaxime, it killed \textit{B. burgdorferi} persisters more effectively than using alone. The drug combination of 40 μg/ml azlocillin and 80 μg/ml cefotaxime kills doxycycline persisters more effectively (less than 10 cells) compared to other combinations showed in the Fig. 5. Further, we also tested whether the doxycycline-tolerant persisters population that were treated with azlocillin have acquired resistance to drugs or persisters formed stochastically tolerating antibiotic stimuli. As our studies were conducted in \textit{in vitro}, several factors like influence of host, immune response and tissue penetration etc were not taken into account. From our observation, we found persisters survived stochastically and didn't acquire any antibiotic resistance, the same phenomenon was also observed by other researchers in \textit{B. burgdorferi}\textsuperscript{19,29}. Some researchers also observed resistant \textit{B. burgdorferi} to erythromycin drugs but we did not observe any resistant mutants from our results shown in Fig. 4\textsuperscript{45}. The very peculiar feature of \textit{B. burgdorferi} is that it doesn't show any resistance to antibiotics. The severeal attempts made by researchers to raise mutants to amoxicillin and ceftriaxone were not successful\textsuperscript{19}. The time kill studies showed that by 48 hrs 99.9% of \textit{B. burgdorferi} were killed when treated with 20 and 40 μg/ml azlocillin. By 96 hours, all the \textit{B. burgdorferi} from stationary phase cultures were completely killed by azlocillin. We report here for the first time that a FDA approved drugs azlocillin

| Drug name | No mice infected | Ear culture in BSK-II medium | Ear No of DNA copies | Urinary bladder No of DNA copies |
|-----------|-----------------|-----------------------------|----------------------|-------------------------------|
| Azlocillin | 1   | –   | 0  | 0  |
|            | 2   | –   | 0  | 0  |
|            | 3   | –   | 0  | 0  |
|            | 4   | –   | 0  | 0  |
|            | 5   | –   | 0  | 0  |
|            | 6   | –   | 0  | 0  |
|            | 7   | –   | 0  | 0  |
|            | 8   | –   | 0  | 0  |
| Cefotaxime | 1   | +   | 179 | 117 |
|            | 2   | –   | 0  | 385 |
|            | 3   | –   | 45 | 1650 |
|            | 4   | –   | 0  | 2425 |
| Doxycycline | 1   | –   | 0  | 0  |
|            | 2   | –   | 0  | 0  |
|            | 3   | –   | 0  | 0  |
|            | 4   | –   | 0  | 0  |
|            | 5   | –   | 0  | 0  |
|            | 6   | –   | 0  | 0  |
|            | 7   | –   | 0  | 0  |
| Saline (control) | 1   | +   | 13088 | 104864 |
|            | 2   | +   | 1125 | 30146 |
|            | 3   | +   | 2212 | 63780 |
|            | 4   | +   | 1020 | 30209 |
| Naive | 1   | –   | 0  | 0  |
|            | 2   | –   | 0  | 0  |
|            | 3   | –   | 0  | 0  |
|            | 4   | –   | 0  | 0  |

Table 1. \textit{In vivo} efficacy of drugs against \textit{B. burgdorferi} in C3H mice. After 7 days of \textit{B. burgdorferi} infection, C3H mice were treated with following drugs once per day for 5 days (Azlocillin – 50 mg/kg, Cefotaxime – 30 mg/kg and Doxycycline – 50 mg/kg). The whole DNA was extracted from urinary bladder and ear and analyzed by qPCR. The \textit{B. burgdorferi} detected in the culture (+) and no \textit{B. burgdorferi} detected in the culture (−).
and cefotaxime more effectively killing both log and stationary phase *B. burgdorferi* cultures at clinically relevant concentrations in *in vitro*. Among these two drugs, azlocillin proved to be the most effective in eradicating the *B. burgdorferi* even at very low concentrations.

### Table 2. *In vivo* efficacy of drugs against *B. burgdorferi* in C3H mice. After 14 days of *B. burgdorferi* infection, C3H mice were treated with following drugs once per day for 5 days (Azlocillin – 50 mg/kg, Cefotaxime – 30 mg/kg and Doxycycline – 50 mg/kg). The whole DNA was extracted from urinary bladder and ear and analyzed by qPCR. The *B. burgdorferi* detected in the culture (+) and no *B. burgdorferi* detected in the culture (−).

| Drug name   | No of mice infected | Ear culture in BSK-II medium | Ear No of DNA copies | Urinary bladder No of DNA copies |
|-------------|---------------------|-------------------------------|----------------------|----------------------------------|
| Azlocillin  |                     |                               |                      |                                  |
|             | 1                   | −                             | 0                    | 0                                |
|             | 2                   | −                             | 0                    | 0                                |
|             | 3                   | −                             | 0                    | 0                                |
|             | 4                   | −                             | 0                    | 0                                |
|             | 5                   | −                             | 104                  | 0                                |
|             | 6                   | −                             | 90                   | 0                                |
|             | 7                   | −                             | 0                    | 0                                |
|             | 8                   | −                             | 0                    | 0                                |
| Cefotaxime  |                     |                               |                      |                                  |
|             | 1                   | +                             | 3999                 | 1264                             |
|             | 2                   | +                             | 3146                 | 135                              |
|             | 3                   | +                             | 1585                 | 423                              |
|             | 4                   | −                             | 218                  | 232                              |
| Doxycycline |                     |                               |                      |                                  |
|             | 1                   | −                             | 0                    | 0                                |
|             | 2                   | −                             | 0                    | 0                                |
|             | 3                   | −                             | 0                    | 0                                |
|             | 4                   | −                             | 111                  | 0                                |
|             | 5                   | −                             | 515                  | 124                              |
|             | 6                   | −                             | 0                    | 0                                |
|             | 7                   | −                             | 110                  | 0                                |
| Saline (control) |             |                               |                      |                                  |
|             | 1                   | +                             | 83766                | 4806                             |
|             | 2                   | +                             | 3255                 | 3177                             |
|             | 3                   | +                             | 102838               | 1161                             |
|             | 4                   | +                             | 372                  | 1940                             |
| Naive       |                     |                               |                      |                                  |
|             | 1                   | −                             | 0                    | 0                                |
|             | 2                   | −                             | 0                    | 0                                |
|             | 3                   | −                             | 0                    | 0                                |
|             | 4                   | −                             | 0                    | 0                                |

### Table 3. *In vivo* efficacy of drugs against *B. burgdorferi* in C3H mice. After 21 days of *B. burgdorferi* infection, C3H mice were treated with following drugs once per day for 5 days (Azlocillin – 50 mg/kg and Doxycycline – 50 mg/kg). The whole DNA was extracted from urinary bladder and ear and analyzed by qPCR. The *B. burgdorferi* detected in the culture (+) and no *B. burgdorferi* detected in the culture (−).
It is shown that during doxycycline-persister formation many genes are differentially expressed compared to normal growth cycle of B. burgdorferi. A total of 35 genes were up-regulated two-fold and 33 genes were down-regulated more than two-fold. The up-regulated genes consisted of different genes including transporter genes, bacterial envelope protein coding genes, genes encoding chemotaxis proteins and the Clp protease gene. It is known that β-lactams binds to ClpP protease and inhibits degradation of misfolded proteins leading to cells death. Inactivation of the ClpXP protease in Staphylococcus aureus even leads to β-Lactam resistance. As azlocillin and cefotaxime are killing doxycycline-tolerant B. burgdorferi persisters, we speculate these drugs may bind to B. burgdorferi ClpP protease. Though there is no evidence that ClpP protease binds to azlocillin, we hypothesized based on available published data. When we docked the azlocillin with five different Clp subunits, azlocillin was found to bind with maximum affinity with ClpX (−9.9 kcal/mol). The ClpX in bacteria has been known as important for protein unfolding, degradation and regulation of protein quality and turnover through controlled proteolysis. The stronger binding of azlocillin with B. burgdorferi ClpX suggest that ClpX might be a potential target for azlocillin in addition to PBP-Bb. However, this observation needs to be experimentally verified in B. burgdorferi.

At the same time, the recent findings showed biosynthesis of bacterial cell wall takes place in non-growing B. burgdorferi stationary phase cultures by continuous synthesis of peptidoglycan. Penicillin-binding proteins (PBPs) play a major role in transglycosylation and transglycosylation steps for peptidoglycan synthesis. The β-lactams bind to PBPs and prevent either transglycosylation or transglycosylation steps which leads to disruption of bacterial cell wall synthesis. The crystallography structural studies shows azlocillin binds strongly to penicillin-binding protein 3 (PBP 3) of Pseudomonas aeruginosa. Considering these studies, we have performed in silico analysis of azlocillin interacting with penicillin-binding protein of Borrelia burgdorferi (PBP-3Bb).

We have found that azlocillin binds strongly with PBP-3Bb with binding affinity of −8.5 kcal/mol. Based on the co-relation of our in silico studies with the experimental findings of azlocillin binding to PBPs in other bacteria we speculate that PBP-3Bb can be one of potential target for azlocillin. In addition to it, studying of azlocillin binding to alternative targets cannot be excluded.

In this current study, we examined the efficacy of azlocillin and cefotaxime post 7, 14 and 21 infection in C3H mice model. We have inoculated higher dose of B. burgdorferi (2 × 10^5) because they replicate fastly in high titres and spreads to tissue sites effectively. Cefotaxime treatment failed to eradicate the B. burgdorferi infection completely in mice infected for 7 and 14 days. We found both doxycycline and azlocillin cleared Borrelia infection at 7 days of infection. In order to study the relative efficacies of doxycycline and azlocillin in mice we have chosen 14 and 21 days of infection. The severity of infection (carditis and arthritis) is more at 14 and 21 days of infection. Doxycycline did not cleared B. burgdorferi completely in all the mice post 14 and 21 days of infection. B. burgdorferi DNA is detected in 3 of 7 mice post 14 days infection and 1 of 3 mice post 21 days infection of doxycycline treatment. Though the azlocillin eliminated B. burgdorferi infection completely in all the mice infected for 21 days still 2 of 8 mice infected for 14 days has some B. burgdorferi DNA in ear tissues. Azlocillin showed more efficacy than doxycycline post 14 and 21 days of infection. Many studies have also shown that even after longterm treatment with doxycycline and ceftriaxone still some B. burgdorferi DNA was detected in mice and rhesus macaque.

It is well known that in 10–20% of the people treated with Lyme disease have PTLDs. The PTLDs might be either due to presence of persistent bacteria or due to its residual particles left over after the infection. Irrespective of causing factors for PTLDs, effective treatment of Lyme patients with more potent drugs can minimize exposure of patients to infection which can prevent PTLDs.

As it is not convenient to use intravenous drugs like azlocillin for treatment compared to oral available drugs, experiments are ongoing for developing oral delivery of azlocillin. Further efficacy studies should be done by long term treatment with azlocillin to check whether it can clear the B. burgdorferi in all the infected mice completely. These results are very encouraging to conduct further in vivo studies on different B. burgdorferi strains. Though azlocillin showed good efficacy in C3H mice model, further studies should be done in in vivo persisters model to prove whether these drugs have potential to eliminate persisters or not. In addition to it, further additional preclinical and clinical studies should conduct for repurposing these drug molecules and clinical acceptance, thereafter.

Materials and Methods

Bacterial strains and culture. The low passage B. burgdorferi sensu stricto strain JLB31 was (generously provided by Dr. Linden Hu Tufts University, Boston, MA, USA) cultured in Barbour-Stoenner-Kelly II (BSK-II) complete medium supplemented with 6% rabbit serum (Sigma, St.Louis, MO, USA). The cultures were incubated in sterile 50 mL falcon tubes (Corning Incorporated, Corning, NY, USA) at 33 °C for 3–7 days in 5% CO2 incubator without antibiotics.

Semisolid plating was chosen to obtain the exact count of the growing borrelial colonies as colony forming units (CFU). We performed semisolid plating procedure as described by Jenny A. Hyde et al. The 2X BSK-II medium was prepared in the following manner. To the 500 ml of CMRL-1066 medium: 50 g of bovine serum albumin (Sigma), 5 g neopeptone (BD), 6.6 g HEPES acid (Sigma), 0.7 g sodium citrate (Sigma), 5 g glucose (Sigma), 2 g yeastolate (BD), 2.2 g sodium bicarbonate (Fisher), 0.8 g sodium pyruvate (Sigma), 0.4 g N-acetyl-glucosamine (Sigma) were added and mixed thoroughly. Finally pH of the medium was adjusted to 7.6 and filtered through 0.2 μm filter units. For plating the medium was dispensed in the following way. The 100 ml of 2X BSK-II medium prewarmed at 55 °C was mixed with 100 ml 1.7 ml of agarose (55 °C) and 14 ml sterilized rabbit serum and equilibrated to 55 °C. Then 10 ml of equilibrated BSK-II medium was dispensed into 60-mm petri dishes as bottom agar and allowed to solidify. Finally, the sample was resuspended in 0.5 ml fresh BSK-II medium and mixed with 10 ml of BSK-II agarose medium (55 °C) and poured as a top agar. The plates were incubated in the incubator with 5% CO2 at 33 °C for minimum of 21 days. The white visible colonies were counted after 21 days for the analysis.
Antimicrobial agents. The 10 mM of drug stocks of Azlocillin sodium salt (Cayman chemicals, Ann Arbor, MI), Cefotaxime acid (Cayman chemicals) and Doxycycline (sigma) were prepared by dissolving in sterile distilled water. The 10 mM Mitomycin C stock was prepared by solubilizing in DMSO.

Dose-dependent killing of *B. burgdorferi*. The dose-dependent killing of *B. burgdorferi* was performed with log phase (3 days old) and stationary phase (7 days to 10 days old). To determine efficacy of drugs, 2 × 10⁶/ml of *Borrelia* were used from log and stationary phase cultures and grown in BSK-II medium in 48-well plates with drugs at varying concentrations ranging from 1.25, 2.5, 5, 10, 20, 40 and 80 μg/ml. The *Borrelia* cultures were incubated at 33°C with 5% CO₂ for 5 days. After 5 days the cultures were centrifuged at 13,000 rpm for 10 minutes. Then the pellets were washed, resuspended in 0.5 ml of fresh BSK-II medium and serially diluted. Finally, the cultures diluted in 0.5 ml BSK-II medium were mixed with 10 ml of BSK agarose and poured as top agar. Plates were incubated at 33°C with 5% CO₂ up to 21 days and visible colonies were counted. The experiments were done at least thrice in triplicates.

Determining efficacy of drugs on doxycycline tolerant persisters. The 10⁶/ml of *Borrelia* taken from log and stationary phase were cultivated with varying doxycycline concentrations of 2.5, 5 and 10 μg/ml. The doxycycline cultivated *Borrelia* cultures were incubated in 48-well plates for 3 days at 33°C with 5% CO₂. Then the cultures were centrifuged for 10 minutes at 13,000 rpm. The remaining doxycycline tolerant *Borrelia* pellets were washed and incubated with 1 ml of BSK-II medium containing drugs of varying concentrations for 7 days. As a control doxycycline tolerant *Borrelia* obtained were also resuspended again with doxycycline concentrations of 2.5, 5 and 10 μg/ml. After incubation for 7 days the cultures were pelleted, washed and resuspended in 0.5 ml of fresh BSK-II medium. Then the semisolid plating was done by mixing cultures diluted in 0.5 ml BSK-II medium with 10 ml of BSK agarose and poured as top agar. Plates were incubated at 33°C with 5% CO₂ up to 21 days. The white visible colonies were counted for generating persister curve. All the experiments were done at least thrice with triplicates.

Time-dependent killing studies. Time kill studies were performed with *Borrelia isolate JLB31 (B. burgdorferi s.s.)* to determine the rate of antimicrobial activity of azlocillin. The 10⁶ per ml *Borrelia* were grown in BSK-II medium with azlocillin at concentrations 20 and 40 μg/ml and doxycycline at concentrations 5 and 10 μg/ml. BSK-II medium with no drugs was used as a control. At time intervals of 2, 6, 10, 24, 48, 96 and 144 hours *B. burgdorferi* cultures were centrifuged for 10 minutes at 13000 rpm and the pelset was resuspended in 0.5 ml of fresh BSK-II medium, serially diluted, mixed with 10 ml of BSK agarose and poured as top agar. After 21 days antibacterial activity was analyzed by counting bacteria colonies at all the time points performed. The experiment was done once with triplicates.

In vivo testing of drugs in C3H/HeN mice. Four weeks old female C3H/HeN mice, were purchased from Charles River Laboratories, Wilmington, Massachusetts. All mice were maintained in the pathogen-free animal facility according to animal safety protocol guidelines at Stanford University under the protocol ID APLAC-30105. All experiments were in accordance with protocols approved by the Institutional Animal Care and Use Committee of Stanford University. The mice were infected intradermally with 0.1 ml BSK medium containing 2 × 10⁶ *B. burgdorferi* JLB31. On the 7, 14 and 21 days of infection, the mice were intraperitoneally administered a daily dose of drugs, azlocillin (50 mg/kg), cefotaxime (30 mg/kg) and doxycycline (50 mg/kg) for 5 consecutive days (Tables 1, 2 and 3). After 48 hours of the last dose of administering compounds, the mice were sacrificed and their urinary bladders, ears, and hearts were cultured in BSK-II medium. The cultures were evaluated for the presence of motile spirochetes after 21 days using the dark-field microscopy. The DNA was extracted from urinary bladder and ear. If the *B. burgdorferi* was observed in any one of the organ in the mice, the animal was considered as infected. The absence of *B. burgdorferi* propagation marked the effectiveness of the treatment in these organisms.

Quantitative Real-time PCR (qPCR) analysis of *B. burgdorferi* DNA from tissues. Urinary bladder, ear punches (20 mg per sample) were homogenized and DNA was extracted using the NucleoSpin tissue kit according to the manufacturer’s instructions (Düren, Germany). qPCR from above tissues were performed in blinded samples using three oligonucleotides, two primers and a probe for *B. burgdorferi* Fla-B gene. These primers were listed as follows: Fla-B primers Flab1F 5′-GCAGCTATGTTGCAAATCTTTTC-3′, Flab1R 5′-AACTGCTGACCCTACCGCTTT-3′ and TAMRA Probe 5′-TACCCTGAGCTACAGAATACTTT-3′ according to the published protocol. The amplification protocol consisted of 10 min at 95°C, followed by 40 cycles of amplification (95°C for 15 s and 60°C for 1 min). A negative result was assigned where no amplification occurred or if the threshold cycle (CT) was greater than 36. Reactions were performed in duplicate for each sample. Results were plotted as the number of *Borrelia* per microgram of tissue. The lower limit of detection was 1 to 100 copies of *B. burgdorferi* Fla-B DNA per mg of tissue. In addition to standard laboratory measures to prevent contamination, negative controls (containing PCR mix, Fla-B primers, and Taq polymerase devoid of test DNA) were included.

Molecular docking. The three-dimensional structure of pBP of *B. burgdorferi* was not available, so it was built using homology modelling by employing SWISS-MODEL. The p-cillin-binding protein (PBP) of *P. aeruginosa* was identified as the homologous protein using BLASTP and hence it was used as the template for building the three-dimensional structure for the *borrelia* PBP. The quality of the modeled structure was verified using Ramachandran plot (Laskowski et al., 1993 and superimposition of modeled structure with that of the template structure was carried using Chimera. Azlocillin was docked with modeled structure of *borrelia* PBP using AutoDock Vina. Molecular interaction between Azlocillin and *borrelia* PBP was analyzed using Discovery
Studio visualizer (version 4.0). Similarly, molecular modeling and docking studies were carried out for five of the protease proteolytic subunits of B. burgdorferi.

**Statistical analysis.** Statistical analysis was performed using GraphPad Prism 7 software. Data sets were analyzed by two-way ANOVA with Tukey's multiple comparisons test for pair-wise comparisons. Significant p values are indicated as ****p < 0.0001 and *p < 0.05.

Received: 21 June 2019; Accepted: 27 January 2020; Published online: 02 March 2020

**References**

1. Baneth, G. Tick-borne infections of animals and humans: a common ground. *International journal for parasitology* **44**, 591–596, https://doi.org/10.1016/j.ijpara.2014.03.011 (2014).
2. Wag, D. *et al.* Borrelia mediator of arthritis in Borrelia metal transporter A (BmTα) binding small molecules by manganese transport inhibition. *Drug design, development and therapy* **9**, 805 (2015).
3. CDC. [https://www.cdc.gov/lyme/stats/humancauses.html](https://www.cdc.gov/lyme/stats/humancauses.html).
4. Wormser, G. P. *et al.* The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* **43**, 1089–1134, https://doi.org/10.1086/508667 (2006).
5. Shemenski, J. Cimetidine as a novel adjunctive treatment for early stage Lyme disease. *Medical hypotheses*, https://doi.org/10.1016/j.mehy.2016.03.015 (2016).
6. Halperin, J. J. Lyme disease: a multisystem infection that affects the nervous system. *Continuum* **18**, 1338–1350, https://doi.org/10.1212/CON.0000423850.24900.3a (2012).
7. Borchers, A. T., Keen, C. L., Huntley, A. C. & Gershwin, M. E. Lyme disease: a rigorous review of diagnostic criteria and treatment. *Journal of autoimmunity* **57**, 82–115, https://doi.org/10.1016/j.jaut.2014.09.004 (2015).
8. Pothineni, V. R. *et al.* Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening. *Drug Des Dev Ther* **10**, 1307–1322, https://doi.org/10.2147/DDDT.S101486 (2016).
9. Klempern, M. S. *et al.* Treatment trials for post-Lyme disease symptoms revisited. *The American journal of medicine* **126**, 665–669, https://doi.org/10.1016/j.amjmed.2013.02.014 (2013).
10. Bockenstedt, L. K. & Radolf, J. D. Xenodiagnosis for posttreatment Lyme disease syndrome: resolving the conundrum or adding to it? *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* **58**, 946–948, https://doi.org/10.1093/cid/ciu942 (2014).
11. Feng, J. *et al.* Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library. *Emerging microbes & infections* **3**, e49, https://doi.org/10.1017/emii.2014.53 (2014).
12. Feng, J. *et al.* Stationary phase persistor/biofilm microcolony of Borrelia burgdorferi causes more severe disease in a mouse model of Lyme arthritis: implications for understanding persistence, Post-treatment Lyme Disease Syndrome (PTLDS), and treatment failure. *Discovery medicine* **27**, 125–138 (2019).
13. Hodzic, E., Feng, S., Holden, K., Freet, K. J. & Barthold, S. W. Persistence of Borrelia burgdorferi following antibiotic treatment in mice. *Antimicrobial agents and chemotherapy* **52**, 1728–1736, https://doi.org/10.1128/AAC.01050-07 (2008).
14. Diterich, I., Rauter, C., Kirschning, C. J. & Hartung, T. Borrelia burgdorferi-induced tolerance as a model of persistence via immunosuppression. *Infection and immunity* **71**, 3979–3987 (2003).
15. Straubinger, R. K., Summers, B. A., Chang, Y. F. & Appel, M. J. Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. *Journal of clinical microbiology* **35**, 111–116 (1997).
16. Embers, M. E. *et al.* Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. *PloS one* **7**, e29914, https://doi.org/10.1371/journal.pone.0029914 (2012).
17. Marques, A. *et al.* Xenodiagnosis to detect Borrelia burgdorferi infection: a first-in-human study. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* **58**, 937–945, https://doi.org/10.1093/cid/ciq39 (2014).
18. Gucoton, J. J. *et al.* Detection of Borrelia burgdorferi DNA by polymerase chain reaction in protein fluid from patients with Lyme arthritis. *The New England journal of medicine* **330**, 229–234, https://doi.org/10.1056/NEJM199412293302403 (1994).
19. Sharma, B., Brown, A. V., Matluck, N. E., Hu, L. T. & Lewis, K. Borrelia burgdorferi, the causative Agent of Lyme Disease, Forms Drug-Tolerant Persistor Cells. *Antimicrobial agents and chemotherapy* **59**, 4616–4624, https://doi.org/10.1128/AAC.00884-15 (2015).
20. Klempern, M. S., Noring, R. & Rogers, R. A. Invasion of human skin fibroblasts by the Lyme disease spirochete, Borrelia burgdorferi. *The Journal of infectious diseases* **167**, 1074–1081 (1993).
21. Zhang, J. R., Hardham, J. M., Barbour, A. G. & Norris, S. J. Antibiotic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. *Cell* **99**, 275–285 (1997).
22. Sapi, E. *et al.* Evidence of In Vitro Existence of Borrelia Biofilm in Borrelial Lymphocytomas. *European journal of microbiology & immunology* **6**, 9–24, https://doi.org/10.1556/1886.2015.00049 (2016).
23. Sapi, E. *et al.* Characterization of biofilm formation by Borrelia burgdorferi *in vitro*. *PloS one* **7**, e48277, https://doi.org/10.1371/journal.pone.0048277 (2012).
24. Embers, M. E., Ramamoorthy, R. & Philipp, M. T. Survival strategies of Borrelia burgdorferi, the etiologic agent of Lyme disease. *Microbes and infection* **6**, 312–318 (2004).
25. Feng, J., Auwaert, P. G. & Zhang, Y. Drug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptoycin, cefoperazone and doxycycline. *PloS one* **10**, e0117207, https://doi.org/10.1371/journal.pone.0117207 (2015).
26. Potheni, V. R. *et al.* Screening of NCI-DTP library to identify new drug candidates for Borrelia burgdorferi. *The Journal of antibiotics* **70**, 308–312, https://doi.org/10.1038/ja.2016.131 (2017).
27. Hunfeld, K. P., Kraiczky, P., Wielchella, T. A., Schafer, V. & Brade, V. New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances. *European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology* **19**, 27–32 (2000).
28. Feng, J., Weitner, M., Shi, W., Zhang, S. & Zhang, Y. Eradication of Biofilm-Like Microcolony Structures of Borrelia burgdorferi by Daptomycin and Daptomycin but not Mitomycin C in Combination with Doxycycline and Cefuroxime. *Frontiers in microbiology* **7**, 62, https://doi.org/10.3389/fmicb.2016.00062 (2016).
29. Caskey, J. B. & Embers, M. E. Persistor Development by Borrelia burgdorferi Populations In Vitro. *Antimicrobial agents and chemotherapy* **59**, 6288–6295, https://doi.org/10.1128/AAC.00883-15 (2015).
30. Newton, P. N. *et al.* Pharmacokinetics of oral doxycycline during combination treatment of severe falciparum malaria. *Antimicrobial agents and chemotherapy* **49**, 1622–1625, https://doi.org/10.1128/AAC.49.4.1622-1625.2005 (2005).
31. Wu, X. *et al.* Identifying Vancomycin as an Effective Antibiotic for Killing Borrelia burgdorferi. *Antimicrobial agents and chemotherapy* **62**, https://doi.org/10.1128/AAC.01201-18 (2018).
32. Feng, J., Shi, W., Zhang, S. & Zhang, Y. Persister mechanisms in Borrelia burgdorferi: implications for improved intervention. *Emerging microbes & infections* 4, e51, https://doi.org/10.1038/emi.2015.51 (2015).

33. Levin, S. & Harris, A. A. Principles of combination therapy. *Bulletin of the New York Academy of Medicine* 51, 1020–1038 (1975).

34. Ren, J., NettleSHIP, J. E., Males, A., Stuart, D. I. & Owens, R. J. Crystal structures of penicillin-binding protein 3 in complexes with azlocillin and cefepiram in both acylated and deacylated forms. *FEBS letters* 590, 288–297, https://doi.org/10.1002/1873-3468.12054 (2016).

35. Hodzic, E., Imai, D., Feng, S. & Barthold, S. W. Resurgence of persisting non-cultivable Borrelia burgdorferi following antibiotic treatment in mice. *Plos one* 9, e86907, https://doi.org/10.1371/journal.pone.0086907 (2014).

36. Lasky, C. E., Olson, R. M. & Brown, C. R. Macrophage Polarization during Murine Lyme Borreliosis. *Infection and immunity* 83, 2627–2635, https://doi.org/10.1128/IAI.00349-15 (2015).

37. Phillips, L., Caldebras, E., Moreno, F. & Baquero, F. Induction of the SOS response by new 4-quinolones. *J. Antimicrob Chemother* 20, 631–638 (1987).

38. Dorr, T., Vulic, M. & Lewis, K. Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. *Plos Biol* 8, e1000317, https://doi.org/10.1371/journal.pbio.1000317 (2010).

39. Germain, E., Castro-Roa, D., Zenkin, N. & Gerdes, K. Molecular mechanism of bacterial persistence by HipA. *Mol. Cell.* 52, 248–254, https://doi.org/10.1016/j.molcel.2013.08.045 (2013).

40. Whelton, A., Stout, R. L., Spilman, P. S., Delgado, F. A. & Watson, A. J. The novel therapeutic implications of azlocillin’s dose-dependent pharmacokinetics: contributing physiologic mechanisms and a prospective, cross-over designed trial. *Journal of clinical pharmacology* 27, 491–498 (1987).

41. van der Voet, G. B., Mattie, H. & van Furth, R. Comparison of the antibacterial activity of azlocillin and ticarcillin in vitro and in irradiated neutrophic mice. *J. Antimicrob Chemother* 16, 605–613 (1985).

42. Hugonnet, J. E., Tremblay, L. W., Boshoff, H. L., Barry, C. E. 3rd & Blanchard, J. S. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. *Science* 323, 1215–1218, https://doi.org/10.1126/science.1167498 (2009).

43. Coppens, L. & Klasterisky, J. Comparative study of anti-pseudomonas activity of azlocillin, mezlocillin, and ticarcillin. *Antimicrobial agents and chemotherapy* 15, 396–399 (1979).

44. Sugar, A. M., Chahal, R. S. & Stevens, D. A. A cephalosporin active in vivo against Nocardia: efficacy of cefotaxime in murine model of acute pulmonary nocardiosis. *The journal of hygiene* 91, 421–427 (1983).

45. Terekhova, D., Sartakova, M. L., Wormser, G. P., Schwartz, I. & Cabello, F. C. Erythromycin resistance in Borrelia burgdorferi. *Antimicrobial agents and chemotherapy* 46, 3637–3640 (2002).

46. Baek, I. T. et al. Beta-lactams as selective chemical probes for the in vivo labeling of bacterial enzymes involved in cell wall biosynthesis, antibiotic resistance, and virulence. *Journal of the American Chemical Society* 130, 13400–13409, https://doi.org/10.1021/ja0803349 (2008).

47. Baek, K. et al. Beta-lactam resistance in methillin-resistant Staphylococcus aureus USA300 is increased by inactivation of the ClpX protease. *Antimicrobial agents and chemotherapy* 58, 4593–4603, https://doi.org/10.1128/AAC.02802-14 (2014).

48. Glynn, S. E., Nager, A. R., Baker, T. A. & Sauer, R. T. Dynamic and static components power unfolding in topologically closed rings. *Nature structural & molecular biology* 19, 616–622, https://doi.org/10.1038/nsmb.2288 (2012).

49. McClelland, S. M. et al. Pharmacological inhibition of the ClpX protease increases bacterial susceptibility to host cathelicidin antimicrobial peptides and cell envelope-active antibiotics. *Antimicrobial agents and chemotherapy* 56, 1854–1861, https://doi.org/10.1128/AAC.05131-12 (2012).

50. Scheffers, D. J. & Pinho, M. G. Bacterial cell wall synthesis: new insights from localization studies. *Microbiol Mol. Biol. Rev.* 69, 585–607, https://doi.org/10.1128/MMBR.69.4.585-607.2005 (2005).

51. Pothineni, V. R. et al. In vitro and in vivo evaluation of cephalosporins for the treatment of Lyme disease. *Drug Des Devel Ther.* 12, 2915–2921, https://doi.org/10.2147/DDDT.S149466 (2018).

52. Wormser, G. P. & Schwartz, I. Antibiotic treatment of animals infected with Borrelia burgdorferi. *Clinical microbiology reviews* 22, 387–395, https://doi.org/10.1128/CMR.00004-09 (2009).

53. Bockensted, L. K., Mao, J., Hodzic, E., Barthold, S. W. & Fish, D. Detection of attenuated, noninfectious spirochetes in Borrelia burgdorferi-infected mice after antibiotic treatment. *The Journal of infectious diseases* 186, 1430–1437, https://doi.org/10.1086/345284 (2002).

54. Hyde, J. A., Weening, E. H. & Skare, J. T. Genetic transformation of Borrelia burgdorferi. *Current protocols in microbiology Chapter* 12, Unit 12.14, https://doi.org/10.1002/9780471729259.mc12e04e20 (2011).

55. Waterhouse, A. et al. SWISS-MODEL: homology modelling of protein structures and complexes. *Nucleic acids research* 46, W296–W303, https://doi.org/10.1093/nar/gky427 (2018).

56. Laskowski, R. A., Rullmannn, J. A., MacArthur, M. W., Kaptein, R. & Thornton, J. M. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. *Journal of biomolecular NMR* 8, 477–486 (1996).

57. Pettersen, E. F. et al. UCSF Chimera—a visualization system for exploratory research and analysis. *Journal of computational chemistry* 25, 1605–1612, https://doi.org/10.1002/jcc.20084 (2004).

58. Trotz, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multitreading. *Journal of computational chemistry* 31, 455–461, https://doi.org/10.1002/jcc.21334 (2010).

Acknowledgements

This work was accomplished with a generous support from the Bay Area Lyme Foundation. We are indebted to Dr. Robert Lane (UC Berkley, CA) for his constant support and provision of valuable bacterial strains for the study. We thank Dr. Linden Hu and Dr. Aurélie Kern, Tufts University, Boston, MA, USA for providing bacterial strains and help in establishing studies with C3H mice model. We also thank Laurel. STEM foundation and BioNeoMed research foundation for their generous support.

Author contributions

V.R.P., S.-K.P., A.A., V.V.A.M., M.I., and M.S.A. performed the experiments and analyzed the data. B.S. performed molecular docking studies. V.R.P. and J.R. designed the study and wrote the paper. All authors read and approved the final manuscript.

Competing interests

Venkata Raveendra Pothineni, Mohammed Inayathullah and Jayakumar Rajadas are listed on the following patent titled “Methods and drug compositions for treating Lyme disease” under international patent application no. WO2017124080A1. Venkata Raveendra Pothineni and Jayakumar Rajadas also filed another provisional patent based on this work. All other authors report no conflicts of interest in this work.
